Literature DB >> 33630782

Ptosis as Clinical Presentation in a Patient With Emery-Dreifuss Muscular Dystrophy Type 5.

Konstantinos A A Douglas1, Vivian Paraskevi Douglas, Eric D Gaier, Bart K Chwalisz.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33630782      PMCID: PMC8373992          DOI: 10.1097/WNO.0000000000001187

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN: 1070-8022            Impact factor:   4.415


× No keyword cloud information.
  4 in total

1.  Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies.

Authors:  Chengliang Dong; Peng Wei; Xueqiu Jian; Richard Gibbs; Eric Boerwinkle; Kai Wang; Xiaoming Liu
Journal:  Hum Mol Genet       Date:  2014-12-30       Impact factor: 6.150

2.  Nesprin-1 and -2 are involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for nuclear envelope integrity.

Authors:  Qiuping Zhang; Cornelia Bethmann; Nathalie F Worth; John D Davies; Christina Wasner; Anja Feuer; Cassandra D Ragnauth; Qijian Yi; Jason A Mellad; Derek T Warren; Matthew A Wheeler; Juliet A Ellis; Jeremy N Skepper; Matthias Vorgerd; Beate Schlotter-Weigel; Peter L Weissberg; Roland G Roberts; Manfred Wehnert; Catherine M Shanahan
Journal:  Hum Mol Genet       Date:  2007-08-29       Impact factor: 6.150

3.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

4.  Large-scale modelling of the divergent spectrin repeats in nesprins: giant modular proteins.

Authors:  Flavia Autore; Mark Pfuhl; Xueping Quan; Aisling Williams; Roland G Roberts; Catherine M Shanahan; Franca Fraternali
Journal:  PLoS One       Date:  2013-05-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.